About osimertinib
EGFR tyrosine kinase inhibitor
Used for
- Treats certain EGFR-mutated non-small cell lung cancers, including some cancers after surgery.
- Treats advanced non-small cell lung cancer with specific EGFR mutations.
Usual adult dose
Usually 80 mg by mouth once daily; dosing may change for side effects or other medicines.
Common side effects
- Diarrhea
- Rash and dry skin
- Nail inflammation
- Low blood counts
Important warnings
- May cause serious lung inflammation; seek urgent assessment for new or worsening breathing problems.
- Can affect heart rhythm and heart function; monitoring may be needed.
- May cause eye problems or severe skin reactions.
- Can harm an unborn baby; effective contraception is needed during treatment and afterward.
Pregnancy
May harm an unborn baby. Avoid during pregnancy; use effective contraception during treatment and for six weeks afterward.
Breastfeeding
Do not breastfeed during treatment and for two weeks after the last dose.
Interactions
- Avoid strong CYP3A inducers, such as rifampin, which can reduce osimertinib levels.
- Some medicines that affect heart rhythm may increase the risk of abnormal heartbeats.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.